Pancreatic Cancer Research

ResearcherHiroshima UniversityActive in the last 2 years

Ippei Matsumoto

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-3965-3693; OpenAlex author ID A5015760456, A5044581018, A5062050360, A5070531979. Sources: OpenAlex.

Their work

Papers
49 (first author 4, last author 2)
Trials
0
Grants
0
Labs led
1
Collaborators
188
Papers, trials and grants by year

2011: 1 paper · 2012: 1 paper · 2013: 2 papers · 2014: 2 papers · 2015: 5 papers · 2016: 5 papers · 2017: 4 papers · 2018: 4 papers · 2019: 5 papers · 2020: 1 paper · 2021: 1 paper · 2022: 2 papers · 2023: 7 papers · 2024: 1 paper · 2025: 4 papers · 2026: 4 papers

Papers 49

  1. Conversion surgery for unresectable pancreatic ductal adenocarcinoma with liver metastasis at initial diagnosis: a nationwide multicenter study. Co-author DOI 10.1007/s00535-026-02432-2↗
  2. Successful management of refractory chylous ascites using a Denver shunt following conversion surgery for unresectable locally advanced pancreatic cancer. Last author DOI 10.1007/s12328-026-02376-3↗
  3. Neoadjuvant Chemotherapy With Gemcitabine and S-1 Versus Upfront Surgery for Resectable Pancreatic Cancer: Results of the Randomized Phase II/III Prep-02/JSAP0… Co-author DOI 10.1097/sla.0000000000006730↗
  4. Impact of Stent Type on Surgical Outcomes in Pancreatic Cancer Patients Undergoing Preoperative Biliary Drainage. Co-author DOI 10.1111/den.70229↗
  5. Clinical role of intraperitoneal chemotherapy in patients with pancreatic ductal adenocarcinoma concomitant with occult peritoneal dissemination: A multicenter… Co-author DOI 10.1002/ags3.70001↗
  6. Optimal treatment strategy for patients with pancreatic cancer having positive peritoneal cytology: A nationwide multicenter retrospective cohort study supervi… Co-author DOI 10.1002/jhbp.12074↗
  7. Prognostic Impact of Unplanned Total Pancreatectomy in Pancreatic Ductal Adenocarcinoma: A Retrospective Analysis. Last author DOI 10.1002/jhbp.12176↗
  8. The impact of neoadjuvant therapy in patients with left-sided resectable pancreatic cancer: an international multicenter study. Co-author DOI 10.1016/j.annonc.2024.12.015↗
  9. Outcomes of patients with initially unresectable pancreatic cancer who underwent conversion surgery after FOLFIRINOX or gemcitabine plus nab-paclitaxel chemoth… Co-author DOI 10.1002/jhbp.12066↗
  10. Efficacy and safety of neoadjuvant nab-paclitaxel plus gemcitabine therapy in patients with borderline resectable pancreatic cancer: A multicenter single-arm p… Co-author DOI 10.1002/ags3.12712↗
  11. Randomized phase II trial of chemoradiotherapy with S-1 versus combination chemotherapy with gemcitabine and S-1 as neoadjuvant treatment for resectable pancre… Co-author DOI 10.1002/jhbp.1353↗
  12. Gastrojejunostomy versus endoscopic duodenal stent placement for gastric outlet obstruction in patients with unresectable pancreatic cancer: a propensity score… Co-author DOI 10.1007/s00464-022-09685-x↗
  13. Clinical Practice Guidelines for Pancreatic Cancer 2022 from the Japan Pancreas Society: a synopsis. Co-author DOI 10.1007/s10147-023-02317-x↗
  14. Clinicopathological variables and risk factors for lung recurrence after resection of pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.asjsur.2022.03.043↗
  15. "Conversion surgery" for locally advanced pancreatic cancer: A position paper by the study group at the joint meeting of the International Association of Pancr… Co-author DOI 10.1016/j.pan.2023.06.005↗
  16. Is surgical resection justified for pancreatic ductal adenocarcinoma with distant abdominal organ metastasis? A position paper by experts in pancreatic surgery… Co-author DOI 10.1016/j.pan.2023.07.005↗
  17. Invited Editorial: Comprehensive Analysis of Molecular Biological Characteristics of Pancreatic Ductal Adenocarcinoma Concomitant with Intraductal Papillary Mu… Co-author DOI 10.1245/s10434-022-11713-y↗
  18. Utility of contrast-enhanced harmonic EUS for diagnosis of portal vein invasion by pancreatic cancer. Co-author DOI 10.4103/eus-d-21-00185↗
  19. Improved detection of liver metastasis using Kupffer-phase imaging in contrast-enhanced harmonic EUS in patients with pancreatic cancer (with video). Co-author DOI 10.1016/j.gie.2020.06.051↗
  20. Partial Pancreatic Parenchymal Atrophy Is a New Specific Finding to Diagnose Small Pancreatic Cancer (≤10 mm) Including Carcinoma in Situ: Comparison with Loca… Co-author DOI 10.3390/diagnostics10070445↗
  21. Sustained Elevation of Postoperative Serum Level of Carbohydrate Antigen 19-9 is High-Risk Stigmata for Primary Hepatic Recurrence in Patients with Curatively … Co-author DOI 10.1007/s00268-018-4814-4↗
  22. A single-arm, phase II trial of neoadjuvant gemcitabine and S1 in patients with resectable and borderline resectable pancreatic adenocarcinoma: PREP-01 study. Co-author DOI 10.1007/s00535-018-1506-7↗
  23. FOLFIRINOX for locally advanced pancreatic cancer: Results and prognostic factors of subset analysis from a nation-wide multicenter observational study in Japa… Co-author DOI 10.1016/j.pan.2019.01.001↗
  24. Randomized phase II/III trial of neoadjuvant chemotherapy with gemcitabine and S-1 versus upfront surgery for resectable pancreatic cancer (Prep-02/JSAP05). Co-author DOI 10.1093/jjco/hyy190↗
  25. Decreased serum carbohydrate antigen 19-9 levels after neoadjuvant therapy predict a better prognosis for patients with pancreatic adenocarcinoma: a multicente… Co-author DOI 10.1186/s12885-019-5460-4↗
  26. Health-related quality of life of adjuvant chemotherapy with S-1 versus gemcitabine for resected pancreatic cancer: Results from a randomised phase III trial (… Co-author DOI 10.1016/j.ejca.2018.01.081↗
  27. Impact of avascular areas, as measured by contrast-enhanced harmonic EUS, on the accuracy of FNA for pancreatic adenocarcinoma. Co-author DOI 10.1016/j.gie.2017.05.052↗
  28. Is distal pancreatectomy with en-bloc celiac axis resection effective for patients with locally advanced pancreatic ductal adenocarcinoma? -Multicenter surgica… Co-author DOI 10.1016/j.pan.2017.11.005↗
  29. MAPLE-PD trial (Mesenteric Approach vs. Conventional Approach for Pancreatic Cancer during Pancreaticoduodenectomy): study protocol for a multicenter randomize… Co-author DOI 10.1186/s13063-018-3002-z↗
  30. Retrospective Study of the Correlation Between Pathological Tumor Size and Survival After Curative Resection of T3 Pancreatic Adenocarcinoma: Proposal for Recl… Co-author DOI 10.1007/s00268-017-4077-5↗
  31. Effect of Neoadjuvant Nab-Paclitaxel plus Gemcitabine Therapy on Overall Survival in Patients with Borderline Resectable Pancreatic Cancer: A Prospective Multi… Co-author DOI 10.1159/000478660↗
  32. Association between the Risk Factors for Pancreatic Ductal Adenocarcinoma and Those for Malignant Intraductal Papillary Mucinous Neoplasm. Co-author DOI 10.1159/000481234↗
  33. [A Case of Conversion Surgery for a Patient with Initially Unresectable Pancreatic Cancer with a Pathological Complete Response to S-1 Chemotherapy]. First author PMID 29394577↗
  34. Prognosis after surgical treatment for pancreatic cancer in patients aged 80 years or older: a multicenter study. Co-author DOI 10.1002/jhbp.320↗
  35. Preoperative independent prognostic factors in patients with borderline resectable pancreatic ductal adenocarcinoma following curative resection: the neutrophi… First author DOI 10.1007/s00595-015-1206-3↗
  36. Grade B pancreatic fistulas do not affect survival after pancreatectomy for pancreatic cancer: A multicenter observational study. Co-author DOI 10.1016/j.surg.2016.02.032↗
  37. Adjuvant chemotherapy of S-1 versus gemcitabine for resected pancreatic cancer: a phase 3, open-label, randomised, non-inferiority trial (JASPAC 01). Co-author DOI 10.1016/s0140-6736(16)30583-9↗
  38. Reappraisal of Total Pancreatectomy in 45 Patients With Pancreatic Ductal Adenocarcinoma in the Modern Era Using Matched-Pairs Analysis: Multicenter Study Grou… Co-author DOI 10.1097/mpa.0000000000000579↗
  39. Postoperative prognosis of pancreatic cancer with para-aortic lymph node metastasis: a multicenter study on 822 patients. Co-author DOI 10.1007/s00535-014-1005-4↗
  40. Reappraisal of peritoneal washing cytology in 984 patients with pancreatic ductal adenocarcinoma who underwent margin-negative resection. Co-author DOI 10.1007/s11605-014-2637-7↗
  41. Proposed preoperative risk factors for early recurrence in patients with resectable pancreatic ductal adenocarcinoma after surgical resection: A multi-center r… Co-author DOI 10.1016/j.pan.2015.09.008↗
  42. Postoperative Serum Albumin Level is a Marker of Incomplete Adjuvant Chemotherapy in Patients with Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1245/s10434-014-4280-7↗
  43. Impact of Preoperative Biliary Drainage on Long-Term Survival in Resected Pancreatic Ductal Adenocarcinoma: A Multicenter Observational Study. Co-author DOI 10.1245/s10434-015-4618-9↗
  44. Influence of preoperative anti-cancer therapy on resectability and perioperative outcomes in patients with pancreatic cancer: project study by the Japanese Soc… Co-author DOI 10.1002/jhbp.15↗
  45. [A case of adjuvant surgery for a patient with initially unresectable locally advanced pancreatic cancer (LAPC) with a favorable response to S-1 chemotherapy]. Co-author PMID 25731462↗
  46. 18-Fluorodeoxyglucose positron emission tomography does not aid in diagnosis of pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.cgh.2012.12.033↗
  47. [A case of metachronous pancreatic cancer that developed 4 years after initial pancreatectomy]. First author PMID 24393957↗
  48. [A case of interstitial lung disease associated with gemcitabine treatment in a patient with locally advanced pancreatic cancer following proton beam radiother… First author PMID 23268009↗
  49. A focal mass-forming autoimmune pancreatitis mimicking pancreatic cancer with obstruction of the main pancreatic duct. Co-author DOI 10.1007/s11605-011-1543-5↗

Closest collaborators

The 25 strongest of 188 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Sohei Satoi · 24 shared papers, 2014–2026 · strength 2.25
  2. Masayuki Sho · 21 shared papers, 2014–2026 · strength 1.76
  3. Michiaki Unno · 18 shared papers, 2014–2026 · strength 1.58
  4. Fuyuhiko Motoi · 16 shared papers, 2014–2026 · strength 1.21
  5. Hiroki Yamaue · 17 shared papers, 2014–2024 · strength 1.12
  6. Tsutomu Fujii · 7 shared papers, 2018–2026 · strength 1.11
  7. Mamoru Takenaka · 8 shared papers, 2017–2026 · strength 1.05
  8. Manabu Kawai · 13 shared papers, 2015–2025 · strength 0.99
  9. Goro Honda · 15 shared papers, 2014–2025 · strength 0.98
  10. Takumi Fukumoto · 18 shared papers, 2011–2023 · strength 0.91
  11. Yoshiaki Murakami · 15 shared papers, 2014–2023 · strength 0.86
  12. Keiko Kamei · 5 shared papers, 2017–2026 · strength 0.86
  13. Yoshifumi Takeyama · 8 shared papers, 2017–2026 · strength 0.84
  14. Hirochika Toyama · 9 shared papers, 2011–2026 · strength 0.80
  15. Minako Nagai · 8 shared papers, 2015–2026 · strength 0.78
  16. Masamichi Mizuma · 7 shared papers, 2015–2026 · strength 0.78
  17. Kenichiro Uemura · 12 shared papers, 2015–2026 · strength 0.76
  18. Yosuke Inoue · 4 shared papers, 2023–2026 · strength 0.64
  19. Hiroaki Yanagimoto · 10 shared papers, 2015–2023 · strength 0.63
  20. Satoshi Hirano · 5 shared papers, 2016–2026 · strength 0.63
  21. Daisuke Hashimoto · 4 shared papers, 2023–2026 · strength 0.61
  22. Tomohisa Yamamoto · 6 shared papers, 2015–2025 · strength 0.60
  23. Masanao Kurata · 11 shared papers, 2015–2019 · strength 0.58
  24. Shinichiro Takahashi · 3 shared papers, 2023–2026 · strength 0.56
  25. Dongha Lee · 2 shared papers, 2025–2026 · strength 0.53

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.